Novo Nordisk was Europe’s most valuable company 20 months ago. Today its market capitalization falls behind ASML, LVMH, Hermès, L’Oréal, SAP, Prosus, Siemens, Inditex, Deutsche Telekom, and Santander.
The stock has lost roughly 75% since its June 2024 peak of $142.44, falling from a $640 billion market cap to under $160 billion. Shares dropped another 16% this morning after Novo Nordisk announced that CagriSema, the follow-on obesity drug, did not meet the primary endpoint in the REDEFINE 4 open-label head-to-head trial against Eli Lilly’s Zepbound.
Looking at the data set in front of us today, the structural picture from the company’s own disclosures is consistent: US pricing is resetting lower through MFN and IRA. The pipeline has not delivered the head-to-head readout the bull case relied on. International patents are eroding. And Novo guided for its first revenue decline in modern history in 2026: adjusted sales down 5-13%, which a number of sell-side notes have characterised as on the soft end of expectations.
Stock collapse
The speed of the decline matters. In June 2024, NVO hit $142.44. Then, in sequence: a July 2025 guidance cut after Q2 results disclosed US pricing headwinds (shares dropped roughly 22% in a session). A September 2025 announcement of 9,000 job cuts and DKK 8 billion in restructuring charges under new CEO Maziar Mike Doustdar, which the market reacted to negatively rather than as the standard efficiency narrative such announcements usually carry. February 4, 2026 full-year results guiding adjusted sales growth at -5% to -13% (the stock declined 18% in Copenhagen on the print). And today, the REDEFINE 4 disclosure.
The 52-week range was $43.08 to $93.80 before today’s open. NVO is now trading around $40, a new low. The all-time high was less than two years ago.
Novo now trades at a lower forward multiple than Merck and below Pfizer, which is dealing with its own post-COVID structural decline. Whether that valuation is justified is the real question.
2026 guidance
It is rare to see a company of Novo’s stature guide for a sales decline. This is not a biotech that lost a coin-flip Phase 3. This is the global leader in GLP-1s telling investors that revenue will shrink.
Three structural forces are driving the decline, each on a different timeline.
The November 2025 MFN deal with the Trump Administration cut Wegovy’s government price to $349/month and set Medicare/Medicaid rates at roughly $245/month, a 60-80% reduction from prior list prices. Insulin was capped at $35/month. Lilly took a similar deal (Zepbound at $346/month), so neither company gained competitive advantage, but both lost pricing power permanently in the government channel. The commercial channel is following. Payers who previously paid $800-1,000 per month for Wegovy are now pointing at the government rate and demanding comparable terms.
Internationally, the patent picture is worse than most investors realize. Semaglutide’s compound patent lapsed in Canada in January 2026 after Novo failed to pay a maintenance fee of roughly CAD 250 (on a self reflective note, maybe this story alone should have made me leave). Sandoz and Apotex are preparing generic launches. Dr. Reddy’s has filed in 87 countries. In China, at least 15 manufacturers are in development. Brazil’s federal court denied a patent extension. The US patent thicket (320 applications, 154 granted, settlements pushing generics to roughly 2031-32) provides breathing room domestically, but international operations generated DKK 112 billion in 2025 revenue, and the erosion has started.
Meanwhile, several states have dropped Medicaid coverage for GLP-1 obesity drugs since late 2025: California, Pennsylvania, New Hampshire, South Carolina. Only 13 states still cover them. The IRA’s Round 2 negotiations, effective January 2027, set Ozempic at $274/month (71% below list) and Wegovy at $385/month. With 2.3 million Medicare semaglutide users, that is a massive revenue compression event arriving in twelve months.
CagriSema: a pipeline event
Some analyst notes have framed REDEFINE 4 as “disappointing but manageable.” That framing understates what the readout means commercially. This was the trial set up to show CagriSema could compete with Lilly on superior efficacy in a head-to-head design, and the published metrics do not support that thesis.
The 2.5 percentage point gap on the on-treatment estimand is meaningful. The wider 3.4 point gap on intention-to-treat suggests CagriSema may also have a tolerability or adherence profile that differs from tirzepatide in real-world use. Only 57% of REDEFINE 1 patients reached the highest CagriSema dose, which is consistent with a tolerability ceiling.
Novo’s management pointed to the blinded REDEFINE 11 trial (flexible dosing) and a planned higher-dose CagriSema study as paths to demonstrating “full weight-loss potential.” REDEFINE 11 results aren’t expected until the first half of 2027, by which point Lilly will likely have published retatrutide data and may have an approved orforglipron pill on market.
CagriSema will still likely receive FDA approval in late 2026, based on the REDEFINE 1 and 2 placebo data. Launching a drug behind the market leader on a head-to-head comparison is a different commercial proposition than launching one with a head-to-head win — pricing, formulary positioning, and physician adoption all get harder. The market view that has emerged in recent sell-side commentary is that the obesity market will expand substantially over the next decade, but with price reductions as a meaningful driver of that expansion.
Eli Lilly is pulling ahead
This is the part I think the Novo bull case underweights. Lilly is pulling ahead on efficacy, pipeline breadth, oral convenience, manufacturing capacity, and patent duration, all at once.
By end of Q3 2025, Lilly held 63% of US branded anti-obesity prescription share and 57% of total US GLP-1 scripts. Zepbound’s Q4 US revenue was $4.2 billion (+122% YoY). Full-year 2025 tirzepatide revenue reached $36.5 billion, making it the world’s best-selling drug molecule. Lilly guided 2026 revenue at $80-83 billion, implying roughly 25% growth. Novo guided for a decline.
Three pipeline assets make the gap worse over time.
Orforglipron, Lilly’s oral non-peptide GLP-1, has an FDA decision expected April-May 2026. No food restrictions, no fasting window. It showed favorable results against oral semaglutide in the ACHIEVE-3 diabetes trial. Goldman Sachs projects 60% oral GLP-1 market share by 2030. The administration profile (no fasting, no water restrictions) is the structural reason analysts see the launch as a turning point — if efficacy is comparable in real-world use, the lower-friction option typically captures share faster.
Retatrutide, the triple agonist (GLP-1/GIP/glucagon), showed 28.7% weight loss at 68 weeks in TRIUMPH-4. That is 5+ points above CagriSema’s best showing. NDA filing is projected for late 2026. GlobalData forecasts $15.6 billion in 2031 sales.
Manufacturing: Lilly has committed $50 billion+ in investment since 2020, including a $6.5 billion Texas oral pill facility. Tirzepatide patents extend through the back half of the 2030s, giving Lilly 5-7 more years of US exclusivity than semaglutide.
Truist estimates Lilly’s obesity/diabetes trio could reach $101 billion in combined peak sales worldwide, before retatrutide even enters the market.
The Wegovy pill: one bright spot
Credit where it’s due. Oral Wegovy, approved December 22, 2025 and launched January 5, 2026, reached over 170,000 patients within four weeks. Weekly prescriptions hit roughly 50,000 by late January. TD Cowen noted it generated roughly 15x more prescriptions than injectable Wegovy at the same post-launch stage, and double Zepbound’s trajectory.
But about 90% of those prescriptions are self-pay at $149/month, because formulary coverage for the new formulation is limited. That is great for patient access and terrible for revenue per patient compared to the injectable franchise. CEO Doustdar acknowledged the tension: the pill launch is strong, but “the price hit on the existing business trumps the great pill launch.”
Clinically, oral semaglutide 25mg delivers roughly 13.6% weight loss in all-comers per the published trial data, below the injectable franchise and Zepbound. The administration requirements (fasting, water restrictions) are a real-world adherence variable. The counterargument the bull case has rested on is that if Novo prices the Wegovy pill aggressively enough, share could follow regardless of the convenience gap — a pricing lever that exists in principle but has not yet been pulled at scale.
When orforglipron arrives with comparable efficacy and no fasting requirement, the Wegovy pill’s competitive position narrows. The window is months, not years.
Two views to weigh
I keep coming back to two views of the same data set, and I think the ambivalence is the right response to what the disclosures show.
One view: Novo at 11x earnings has compressed substantially. The GLP-1 market is projected by JP Morgan to reach $100-150 billion by 2030. Novo still has the most prescribed semaglutide franchise globally. The Wegovy pill launch is legitimately strong by the early prescription numbers. The balance sheet, per FY2025 disclosures, shows debt/equity roughly 0.67x post-Catalent with free cash flow guided at DKK 35-45 billion, and the dividend yield is approaching 4%. If the obesity treatment market is multi-winner rather than winner-take-all, the structural case for the franchise is intact.
The other view: there is no clearly positive near-term catalyst before May at the earliest. Orforglipron approval could arrive any day. Post-CagriSema analyst target revisions haven’t all landed yet. European institutional selling may have further to run. Short interest is under 1% of shares outstanding, which is informative because it means the 75% decline has been driven overwhelmingly by long selling, not short pressing — and forced selling from funds that haven’t yet adjusted positions could continue. The fundamental backdrop remains: Lilly has the head-to-head injectable win, will likely have a better oral, and has a triple agonist in late-stage development.
Both views are consistent with the publicly available data. Neither is an instruction to do anything with it. The point of laying both out is that the structural problems described above take quarters to play through, not days, and a reader’s view on what to do with the disclosures is necessarily their own.